Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial
Alimentary Pharmacology & Therapeutics · 18.11.2026
DOI: 10.1111/apt.71100 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 18.11.2026. Verfasst von Riya Khurana und 7 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Functional dyspepsia (FD) frequently coexists with irritable bowel syndrome (IBS), resulting in a complex clinical phenotype characterized by prominent postprandial symptoms and limited treatment options. We compared the efficacy of a low–fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet with traditional dietary advice (TDA) in this population.
Methods
In this multicentre randomized, assessor‐blinded trial, adults fulfilling Rome IV criteria for both FD and IBS were assigned to a low‐FODMAP diet (LFD) or TDA for 6 weeks, with structured dietitian support. The primary endpoint was a combined response, defined by both a ≥ 50‐point reduction in IBS Symptom Severity Scale and a ≥ 30% reduction in Short‐Form Nepean Dyspepsia Index (SFNDI) symptom scores at 6 weeks. Among patients who responded to LFD, FODMAPS were systematically reintroduced from 7 to 12 weeks, and patients who had symptom recurrence were defined as ‘true responders’. Baseline predictors of true LFD response were evaluated using univariable and multivariable logistic regression (CTRI/2025/04/084483).
Results
A total of, 112 participants were randomized (LFD, n = 59; TDA, n = 53; mean age 40.9 ± 15.2 years, 42.8% males). After 6 weeks, the combined IBS‐FD response rates were 59.3% versus 32.1% ( p = 0.005) in the LFD and TDA arms respectively. After FODMAP reintroduction, 32/35 patients (91.4%) had symptom recurrence (true responders). Improvements in symptom and disease‐specific quality‐of‐life scores favoured LFD. Exploratory multivariable predictors of response to LFD were postprandial distress sub‐type and a higher (worse) baseline SF‐NDI quality‐of‐life score.
Conclusion
A low‐FODMAP diet was superior to traditional dietary advice in improving global symptoms and HRQoL in patients with FD–IBS overlap, supporting targeted fermentable carbohydrate restriction as an effective, personalized therapeutic strategy.
Zitieren
APA
Khurana, R., Goyal, M. K., Rakhra, G., Sachdeva, S., Bharadwaj, V., Vaithiyam, V., Dalal, A., & Goyal, O. (2026). Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71100
Vancouver
Khurana R, Goyal MK, Rakhra G, Sachdeva S, Bharadwaj V, Vaithiyam V, et al. Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71100
BibTeX
@article{Khurana2026,
author = {Khurana, Riya and Goyal, Manjeet Kumar and Rakhra, Gurseen and Sachdeva, Sanjeev and Bharadwaj, Vaishali and Vaithiyam, Venkatesh and Dalal, Ashok and Goyal, Omesh},
title = {Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71100}
}
EUVIMED